Table 2.
Adverse events
| Full dose, N = 28 | Escalating dose, N = 34 | P-value | |
|---|---|---|---|
| Adverse events | |||
| At least one adverse event, no. (%) | 25 (89.29) | 29 (85.29) | 0.64 |
| Skin disturbances, no. (%) | 17 (60.71) | 21 (61.76) | 0.93 |
| Neuromuscular side effects, no. (%) | 15 (53.57) | 16 (47.06) | 0.61 |
| Hematologic toxicity, no. (%) | 7 (25) | 5 (14.71) | 0.24 |
| Liver toxicity, no. (%) | 7 (25) | 5 (14.71) | 0.24 |
| Digestive disturbances, no. (%) | 7 (25) | 3 (8.82) | 0.08 |
| Kidney injury, no. (%) | 0 | 1 (2.94) | 1 |
| Management | |||
| Need of specific treatment, no. (%) | 12 (42.86) | 14 (41.18) | 0.89 |
| Referral to a specialist, no. (%) | 12 (42.86) | 15 (44.12) | 0.92 |
| Hospital admission, no. (%) | 1 (3.57) | 2 (5.88) | 0.67 |
| Treatment interruption, no. (%) | 7 (25) | 14 (41.18) | 0.18 |
| Treatment duration, days (SD) | 51.75 (15.4) | 49.4 (21.5) | 0.26 |
| Completed at least 80% of total dose, no. (%) | 21 (75) | 23 (67.65) | 0.53 |
| Completed at least 30 days, no. (%) | 25 (89.29) | 27 (79.41) | 0.29 |
| Maximum dose per day, median grams (SD) | 316.1 (38.7) | 304.5 (26.1) | 0.14 |
no. = number.